PROCYSBI is dosed every 12 hours for continuous cystine control1
The first and only FDA-approved treatment for nephropathic cystinosis with 12-hour dosing, PROCYSBI® (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules works to control cystine levels in adults and children aged ≥1 year.1
- Dosed every 12 hours, twice daily1
- Available in both capsules and tear-open packets
- Proprietary delayed-release technology releases cysteamine gradually for continuous cystine control2-5
- Flexible administration options for your patients, including those with a gastrostomy tube (G-tube)1
References: 1. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules [prescribing information] Horizon. 2. Langman CB, Greenbaum LA, Sarwal M, et al. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol. 2012;7(7):1112-1120. 3. Veys KR, Besouw MT, Pinxten AM, van Dyck M, Casteels I, Levtchenko EN. Cystinosis: a new perspective. Acta Clin Belg. 2016;71(3):131-137. 4. Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA. Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr. 2010;156(1):71-75. 5. Dohil R, Rioux P. Pharmacokinetic studies of cysteamine bitartrate delayed-release. Clin Pharmacol Drug Dev. 2013;2(2):178-185.